World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
114
Citations
45828
World Ranking
4762
National Ranking
181

Pancras C.W. Hogendoorn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Pancras C.W. Hogendoorn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 485 publications — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Pancras C.W. Hogendoorn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Pancras C.W. Hogendoorn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 114 D-Index — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2021 - Member of the Royal Netherlands Academy of Arts and Sciences
  • 2019 - Doctor Honoris Causa, Semmelweis University
  • 2019 - Member of Academia Europaea

Overview

Pancras C.W. Hogendoorn is affiliated with Leiden University Medical Center in the Netherlands. Their research primarily spans the field of Medicine, with a focused concentration on several subfields including Pulmonary and Respiratory Medicine, Rheumatology, Oncology, Infectious Diseases, and the History of Medicine. The scope of research topics features Sarcoma Diagnosis and Treatment, Bone Tumor Diagnosis and Treatments, Histiocytic Disorders and Treatments, Medical History and Innovations, History of Medicine Studies, Bone Health and Treatments, and Lymphoma Diagnosis and Treatment.

Recent publications demonstrate a variety of interests across clinical and pathological studies. Notable papers include:

  • ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition (2021) published in Blood
  • Immunological factors linked to geographical variation in vaccine responses (2023) published in Nature reviews. Immunology
  • Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation (2020) published in The Journal of Pathology Clinical Research
  • Thromboembolic involvement and its possible pathogenesis in COVID-19 mortality: lesson from post-mortem reports (2021) published in PubMed
  • Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases (2021) published in Annals of Diagnostic Pathology

Frequent collaborators in their research include I. F. Hendriks, F. Boer, Paul G. Kemps, Judith V.M.G. Bovée, and Robert M. Verdijk, each contributing to multiple joint publications.

Their work has appeared in a variety of publication venues where they have consistently contributed, including:

  • Vestnik of Saint Petersburg University Medicine
  • Cancers
  • Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  • Journal of Anatomy and Histopathology
  • Blood

In recognition of their academic contributions, they were awarded membership in the Academia Europaea in 2019.

Best Publications

  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*

    Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne

  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Ian Judson;Jaap Verweij;Hans Gelderblom;Jörg T Hartmann;Jörg T Hartmann

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

    M. Fernanda Amary;Krisztian Bacsi;Francesca Maggiani;Stephen Damato

  • Sarcoma derived from cultured mesenchymal stem cells

    Jakub Tolar;Alma J. Nauta;Mark J. Osborn;Angela Panoskaltsis Mortari

  • The Clinical Approach Towards Chondrosarcoma

    Hans Gelderblom;Pancras C.W. Hogendoorn;Sander D. Dijkstra;Carla S. van Rijswijk

  • Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Isabelle Ray-Coquard;Claire Cropet;Martine Van Glabbeke;Catherine Sebban

  • Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;J.-Y. Blay

  • Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

    Neyssa M Marina;Sigbjørn Smeland;Stefan S Bielack;Mark Bernstein

  • Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial

    Penella J. Woll;Peter Reichardt;Axel Le Cesne;Sylvie Bonvalot

  • Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

    Sigbjørn Smeland;Stefan S. Bielack;Jeremy Whelan;Mark Bernstein

  • Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

    Jakob K. Anninga;Hans Gelderblom;Marta Fiocco;Judith R. Kroep

  • Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

    Stefan S. Bielack;Sigbjørn Smeland;Jeremy S. Whelan;Neyssa Marina

  • Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

    Emilie P. Buddingh;Marieke L. Kuijjer;Ronald A J Duim;Horst Bürger

  • Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup

    Ian J. Lewis;Marianne A. Nooij;Jeremy Whelan;Matthew R. Sydes

  • Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study.

    Wim G. Goettsch;Steffan D. Bos;Nancy Breekveldt-Postma;Mariel Casparie

  • The histopathological differential diagnosis of gastrointestinal stromal tumours.

    J F Graadt van Roggen;M L F van Velthuysen;P C W Hogendoorn

  • Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

    Martine Van Glabbeke;Jaap Verweij;Paolo G Casali;Axel Le Cesne

  • Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples.

    Danielle M. de Jong;Sofie Lj Verbeke;Danielle Meijer;Pancras Cw Hogendoorn

  • EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

    J. S. Whelan;S. S. Bielack;N. Marina;S. Smeland

Frequent Co-Authors

Judith V.M.G. Bovée
Judith V.M.G. Bovée Leiden University Medical Center
Karoly Szuhai
Karoly Szuhai Leiden University Medical Center
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Cees J. Cornelisse
Cees J. Cornelisse Leiden University Medical Center
Adrienne M. Flanagan
Adrienne M. Flanagan University College London
Matthew R. Sydes
Matthew R. Sydes University College London
Nicholas A. Athanasou
Nicholas A. Athanasou University of Oxford
Arjan C. Lankester
Arjan C. Lankester Leiden University Medical Center
Jaap Verweij
Jaap Verweij Erasmus University Rotterdam
Peter Hohenberger
Peter Hohenberger Heidelberg University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine in the USA offers a variety of online educational paths that can complement or provide alternatives to traditional MD programs. For nurses aiming to advance their qualifications, consider exploring the cheapest bsn to dnp programs. These allow registered nurses to earn a Doctor of Nursing Practice (DNP) degree online with affordable tuition options.

Pharmacists or pharmacy students may be interested in pursuing advanced credentials through pharm d online programs. These programs offer flexibility for working professionals seeking to expand their career prospects in pharmaceutical care and management.

For those drawn toward healthcare technology and administration, obtaining RHIA certification can open doors. Accredited rhia certification programs online prepare graduates for in-demand roles managing patient data and ensuring health information security.

Finally, if you are considering support roles in healthcare, medical billing and coding is a highly sought-after skillset. Learn about tuition and program options by researching how much is medical billing and coding school before you enroll.

Best Scientists Citing Pancras C.W. Hogendoorn

Trending Scientists

Recently Published Articles